IL202306A - Pharmaceutical preparations containing stabilized thrombin - Google Patents

Pharmaceutical preparations containing stabilized thrombin

Info

Publication number
IL202306A
IL202306A IL202306A IL20230609A IL202306A IL 202306 A IL202306 A IL 202306A IL 202306 A IL202306 A IL 202306A IL 20230609 A IL20230609 A IL 20230609A IL 202306 A IL202306 A IL 202306A
Authority
IL
Israel
Prior art keywords
pharmaceutical compositions
stabilized thrombin
thrombin pharmaceutical
stabilized
compositions
Prior art date
Application number
IL202306A
Other languages
English (en)
Hebrew (he)
Other versions
IL202306A0 (en
Original Assignee
Zymogenetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zymogenetics Inc filed Critical Zymogenetics Inc
Publication of IL202306A0 publication Critical patent/IL202306A0/en
Publication of IL202306A publication Critical patent/IL202306A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
IL202306A 2007-06-15 2009-11-24 Pharmaceutical preparations containing stabilized thrombin IL202306A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US94422407P 2007-06-15 2007-06-15
PCT/US2008/066850 WO2008157304A2 (en) 2007-06-15 2008-06-13 Stabilized thrombin compositions

Publications (2)

Publication Number Publication Date
IL202306A0 IL202306A0 (en) 2010-06-30
IL202306A true IL202306A (en) 2014-07-31

Family

ID=40132545

Family Applications (1)

Application Number Title Priority Date Filing Date
IL202306A IL202306A (en) 2007-06-15 2009-11-24 Pharmaceutical preparations containing stabilized thrombin

Country Status (8)

Country Link
US (1) US8071090B2 (https=)
EP (1) EP2167041B1 (https=)
JP (1) JP5253501B2 (https=)
AU (1) AU2008266094B2 (https=)
CA (2) CA2937487C (https=)
ES (1) ES2397234T3 (https=)
IL (1) IL202306A (https=)
WO (1) WO2008157304A2 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE554397T1 (de) * 2006-12-21 2012-05-15 Sekisui Medical Co Ltd Verfahren zur stabilisierung von alpha-thrombin in einer thrombinhaltigen lösung
RU2657955C2 (ru) 2012-03-06 2018-06-18 Ферросан Медикал Дивайсиз А/С Контейнер под давлением, содержащий гемостатическую пасту
EP2977066A3 (en) 2012-06-12 2016-07-27 Ferrosan Medical Devices A/S Dry haemostatic composition
US9149529B2 (en) 2012-10-24 2015-10-06 Orthovita, Inc. Stable compositions containing thrombin and methods for preparation and use thereof
AU2014283170B2 (en) 2013-06-21 2017-11-02 Ferrosan Medical Devices A/S Vacuum expanded dry composition and syringe for retaining same
IL229134A0 (en) 2013-10-29 2014-03-31 Omrix Biopharmaceuticals Ltd Compounds and methods for stabilizing thrombin activity
JP6489485B2 (ja) 2013-12-11 2019-03-27 フェロサン メディカル デバイシーズ エイ/エス 押し出し増強因子を含んでいる乾燥組成物
IL234246A0 (en) * 2014-08-21 2014-11-30 Omrix Biopharmaceuticals Ltd Stabilized thrombin
AU2015333206B2 (en) 2014-10-13 2019-07-11 Ferrosan Medical Devices A/S. Dry composition for use in haemostasis and wound healing
RU2705905C2 (ru) 2014-12-24 2019-11-12 Ферросан Медикал Дивайсиз А/С Шприц для удерживания и смешивания первого и второго веществ
CA2970223A1 (en) * 2015-03-13 2016-09-22 Chung Chin Sun Method of stabilizing thrombin and composition thereof
CN107771093B (zh) 2015-07-03 2021-06-15 弗罗桑医疗设备公司 用于混合两种组分和用于在存储条件下保持真空的注射器
US11801324B2 (en) 2018-05-09 2023-10-31 Ferrosan Medical Devices A/S Method for preparing a haemostatic composition

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3879369A (en) 1972-05-12 1975-04-22 Abbott Lab Anti-coagulant isolation from malayan pit viper using affinity chromatography
US4696812A (en) 1985-10-28 1987-09-29 Warner-Lambert Company Thrombin preparations
JPS6440433A (en) 1987-08-05 1989-02-10 Green Cross Corp Aqueous liquid composition of thrombin
US5707996A (en) * 1995-11-06 1998-01-13 Macleod Pharmaceuticals, Inc. Pharmaceutical solution and methods for preparation thereof
EP1475098B1 (en) 2002-01-18 2015-08-05 Asahi Kasei Pharma Corporation High-concentration preparation of soluble thrombomodulin
WO2003086332A1 (en) * 2002-04-11 2003-10-23 Dvm Pharmaceuticals, Inc. Antimicrobial wash and carrier solutions, and uses thereof
WO2006009989A1 (en) 2004-06-22 2006-01-26 Zymogenetics, Inc. Thrombin compositions
US20060270015A1 (en) * 2005-05-26 2006-11-30 Dan Pawlak Thrombin purification
JP2006160760A (ja) * 2006-02-03 2006-06-22 Tobishi Pharmaceut Co Ltd 血管壁内膜肥厚抑制剤

Also Published As

Publication number Publication date
IL202306A0 (en) 2010-06-30
WO2008157304A2 (en) 2008-12-24
CA2937487C (en) 2018-01-09
AU2008266094B2 (en) 2014-01-30
WO2008157304A3 (en) 2009-03-12
EP2167041B1 (en) 2012-11-07
CA2687968C (en) 2016-09-27
JP5253501B2 (ja) 2013-07-31
JP2010529997A (ja) 2010-09-02
AU2008266094A1 (en) 2008-12-24
EP2167041A2 (en) 2010-03-31
US8071090B2 (en) 2011-12-06
US20080311104A1 (en) 2008-12-18
CA2687968A1 (en) 2008-12-24
CA2937487A1 (en) 2008-12-24
ES2397234T3 (es) 2013-03-05
AU2008266094A8 (en) 2010-01-21

Similar Documents

Publication Publication Date Title
IL247741A0 (en) pharmaceutical preparations
EP2001498A4 (en) PHARMACEUTICAL COMPOSITIONS
IL194176A0 (en) Pharmaceutical compositions
GB0713625D0 (en) Pharmaceutical compositions
EP2133095A4 (en) PHARMACEUTICAL COMPOSITION
EP2133094A4 (en) PHARMACEUTICAL COMPOSITION
IL202306A (en) Pharmaceutical preparations containing stabilized thrombin
PL2124556T3 (pl) Kompozycje farmaceutyczne
EP2222313A4 (en) PHARMACEUTICAL COMPOSITIONS
PT2966175T (pt) Composições farmacêuticas contendo 17-alfa-propionato de cortexolona
EP2224805A4 (en) PHARMACEUTICAL COMPOSITION
EP2224915A4 (en) PHARMACEUTICAL COMPOSITIONS
GB0608724D0 (en) Novel Pharmaceutical Compositions
GB0707127D0 (en) Pharmaceutical compositions
EP2146695A4 (en) PHARMACEUTICAL COMPOSITIONS
EP2224808A4 (en) PHARMACEUTICAL COMPOSITION
GB0709811D0 (en) Pharmaceutical compositions
GB0610322D0 (en) Novel pharmaceutical compositions
GB0712454D0 (en) Pharmaceutical compositions
GB2454923B (en) Pharmaceutical compositions
IL201394A0 (en) Niacin - based pharmaceutical compositions
HU0700755D0 (en) Pharmaceutical compositions containing capsaicionid
GB0706657D0 (en) Pharmaceutical compositions
GB0709603D0 (en) Pharmaceutical compositions
GB0611079D0 (en) Pharmaceutical compositions

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees